LeMaitre Vascular (NASDAQ:LMAT) Downgraded by Zacks Research to Hold

Zacks Research lowered shares of LeMaitre Vascular (NASDAQ:LMAT) from a strong-buy rating to a hold rating in a report issued on Monday,Zacks.com reports.

Several other research firms have also recently issued reports on LMAT. Barrington Research restated an “outperform” rating and set a $120.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, June 3rd. Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings lowered LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, June 30th. Wells Fargo & Company lifted their price target on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Finally, Citizens Jmp upped their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $105.70 on Monday. The firm has a 50 day simple moving average of $98.45 and a 200-day simple moving average of $97.58. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20. The firm has a market cap of $2.42 billion, a PE ratio of 39.00, a P/E/G ratio of 2.88 and a beta of 0.52. LeMaitre Vascular has a 1-year low of $79.00 and a 1-year high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. The firm had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. LeMaitre Vascular’s revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, equities analysts expect that LeMaitre Vascular will post 3 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Thursday, May 21st were issued a dividend of $0.25 per share. The ex-dividend date was Thursday, May 21st. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s payout ratio is presently 36.90%.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,881 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the transaction, the chief executive officer owned 1,430,019 shares in the company, valued at $155,428,765.11. The trade was a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $111.10, for a total value of $560,388.40. Following the completion of the sale, the director directly owned 3,942 shares of the company’s stock, valued at $437,956.20. The trade was a 56.13% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 54,453 shares of company stock valued at $5,906,174. Company insiders own 7.40% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently bought and sold shares of LMAT. Sound Income Strategies LLC grew its position in LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 183 shares in the last quarter. Catalyst Capital Advisors LLC acquired a new position in shares of LeMaitre Vascular during the first quarter worth $32,000. Geneos Wealth Management Inc. lifted its position in shares of LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 398 shares in the last quarter. EverSource Wealth Advisors LLC purchased a new position in shares of LeMaitre Vascular in the second quarter valued at $47,000. Finally, GAMMA Investing LLC boosted its stake in shares of LeMaitre Vascular by 32.7% in the fourth quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 179 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.